|
Published by: Visiongain
Published: Nov. 1, 2001
Table of Contents
1. Introducing Cancer: Introducing Cancer as a Disease
1.1 Normal cell growth
1.1.1 Growth and replication in normal cells
Fig. 1 Diagrammatic overview of cell replication in normal human cells
Fig. 2 DNAreplication
1.1.2 Cyclins and cyclin dependent kinases
1.2 Apoptosis - orchestrated cell death
Fig. 3 Apoptosis
1.2.1 What is the relevance of apoptosis in cancer?
1.3 The genetics of cancer
1.3.1 Proto-oncogenes
1.3.2 Tumor suppressor genes
1.3.3 Cellular replication, apoptosis and p53
Graph 1 p53 expression in breast cancer
1.3.4 TGF-beta and tumorigenesis
1.3.5 Malignant progression and TGF-beta
Graph 2 bcl-2 expression in cancer indications
1.3.6 'Survival' gene bcl-2
1.3.7 c-myc expression, apoptosis and transformation
1.4 Angiogenesis and cancer
1.5 The multistage development of cancer
1.6 Cell types commonly associated with cancer
1.7 Immortality in cancer cells
1.8 Key properties of malignant cells
2. Epidemiology: Epidemiology of Cancer
Graph 3 UK incidence males 1997
Graph 4 UK incidence females 1997
2.1 How many people alive today have suffered with cancer?
2.2 How many new are cases are expected to occur in 2001?
2.3 Cancer and survival
Graph 5 UK males:likelihood of 5 year survival
Graph 6 UK females:likelihood of 5 year survival
3. Current Therapy: The Current Approach to Cancer Therapy
3.1 Surgery for cancer
3.2 Radiotherapy
3.2.1 X-rays
3.2.2 Gamma radiation
3.2.3 Internal radiotherapy
3.2.4 Intra-operative irradiation
3.2.5 Particle beam irradiation therapy
3.3 Radiosensitizers and radioprotectors
3.4 Radioimmunotherapy
3.5 Chemotherapy
3.5.1 How does chemotherapy work?
3.5.2 Current methods for administration of chemotherapeutic agents
4. Approved Drugs: Current Anti-Cancer Drugs Approved for Clinical Use
4.1 Antineoplastics
4.2 The Antimetabolites
4.3 The Alkylating agents
4.4 Other anti-cancer chemotherapies
4.4.1 Biological response modifiers
4.4.2 Enzyme technologies
4.4.3 Synthetic hormones
4.4.4 Antibody technologies
4.5 FDAapproved drugs
Table 1 Anti-cancer drugs awarded FDAapproval and currently available
commerically
4.6 New oncology drugs approved since 1995
Table 2 New drugs for the treatment of cancer approved by the FDAin 2001
Table 3 New drugs for the treatment of cancer approved by the FDAin 2000
Table 4 New drugs for the treatment of cancer approved by the FDAin 1999
Table 5 New drugs for the treatment of cancer approved by the FDAin 1998
Table 6 New drugs for the treatment of cancer approved by the FDAin 1997
Table 7 New drugs for the treatment of cancer approved by the FDA in
1996
Table 8 New drugs for the treatment of cancer approved by the FDAin 1995
5. Cancer Vaccines: The Implementation of Vaccines in the Fight Against
Cancer
5.1 Types of whole cell cancer vaccine
5.2 Antigen vaccines
5.3 Delivery of antigen vaccines
5.4 Cytokines, surface proteins and vaccines
5.5 Antibody vaccines
5.6 Additional components in cancer vacines
5.7 Cancer vaccine companies
5.7.1 AVIBioPharma
5.7.2 Biomira
5.7.3 Cell Genesys
6. Antisense: Antisense Therapy
6.1 What is antisense therapy?
6.2 Companies working with antisense
6.2.1 Genta
6.2.2 AVI BioPharma
6.2.3 ISISPharmaceuticals
7. Pharmacogenomics: Pharmacogenomics and Cancer Therapy
7.1 The impact of pharmacogenomics
7.1.1 More powerful medicines
7.1.2 Better, safer drugs the first time
7.1.3 Drug dosage and pharmacogenomics
7.1.4 Pharmacogenomics and screening
7.1.5 Pharmacogenomics and vaccine strategy
7.1.6 Pharmocogenomics and drug discovery/approval
7.1.7 Pharmacogenomics and healthcare
7.2 Pharmacogenomics and cancer
7.3 Future, finance and pharmacogenomics
8. TRAIL/Apo-2L: The TNF-Related Apoptosis-Inducing Ligand
TRAIL (Apo-2L) and its potential in anti-cancer therapy
9. New Medicines: New Medicines in Development for the Treatment of
Cancer
9.1 Medicines in development for cancer
9.2 Therapeutic compounds on the horizon for the treatment of cancer
Table 9 New drugs in late phase clinical development for cancer
indications
Graph 7 Number of new drugs in development for use in the treatment of
the given cancer indication
10. Companies in the Sector: Development and Marketing Companies
Involved in the Sector
10.1 ALZA Oncology
Table 10 Sales attributed to Doxil and Ethyol
10.2 AVIBioPharma
10.3 Axys Pharmaceuticals
10.4 Bayer
10.5 Biomira
10.6 Bristol-Myers Squibb
10.7 Cell Therapeutics (CTI)
10.8 Cell Genesys
10.9 Genta
10.10 GlaxoSmithKline
Table 11 Sales attributed to oncology and emesis products
10.11 Guilford Pharmaceuticals
10.12 Immunex
10.13 Immunomedics
10.14 ISISPharmaceuticals
10.15 The Liposome Company
10.16 Matrix Pharmaceuticals
10.17 OXiGENE
10.18 Vion Pharmaceuticals
11. Product Portfolios: Products and Pipeline Products from Leading
Companies in the Sector
11.1 ALZA Oncology
11.2 AVI BioPharma
11.3 Axys Pharmaceuticals
11.4 Bayer Pharmaceuticals
11.5 Biomira
11.6 Bristol-Myers Squibb
11.7 Cell Therapeutics (CTI)
11.8 Cell Genesys
11.9 Genta
11.10 GlaxoSmithKline
11.11 Guilford Pharmaceuticals
11.12 Immunex
11.13 Immunomedics
11.14 ISISPharmaceuticals
11.15 The Liposome Company
11.16 Matrix Pharmaceuticals
11.17 OXiGENE
11.18 Vion Pharmaceuticals
12. Visiongain Analysis: visiongain Analysis on the Industry Sector:
Novel Approaches for the Treatment of Cancer
12.1 Antisense technology
12.2 Anti-cancer vaccine strategies
12.3 TRAIL/Apo-2L as a new treatment for cancer
12.4 Implementing pharmacogenomics in the treatment of cancer
12.5 Liposomal encapsulation and cancer therapy
12.6 Novel approaches to direct tumor delivery
12.6.1 Gliadel wafer
12.6.2 The TAPETsystem
12.7 Final visiongain comment
Appendix 1: FDAterminology
Appendix 2: Glossary of terms and acronyms
Appendix 3: About visiongain
AbstractWhat is a cancer drug delivery system?
Drug delivery systems are a growing sector of the pharmaceutical industry. The backbone of the sector is hinged on research and development into new ways of delivering therapeutic agents for the treatment of cancer and related diseases. A drug delivery system can be either a new and innovative method of administering a drug or a novel twist on an existing drug.
Why is research into cancer drug delivery systems necessary?
Many anti-cancer drugs and therapies are as well known for the associated side effects as their therapeutic benefit. These instantly recognisable side effects can necessitate reduction of dosage of a drug, and can have a serious effect on the well-being of patients. New cancer drug delivery systems are in development to minimise harm to non-cancerous cells, whist enhancing the effect on the tumour itself.
Why buy this report?
Cancer is recognized as the second most common cause of death in the developed world, and can arise as a result of a number of factors. The multifactorial nature of cancer breeds a wealth of potential target genes, enzymes, proteins and hormones. This means that at any one time, there can be more new drugs in development than types of cancer itself. With $26.4 billion invested in the drug industry in 2000, it has established a major market for development and research.
Who should buy this report?
Drug development is inherently risky, and with the potential for failure at any stage of development, it is essential to be well informed. Cancer Drug Delivery Systems by Pharma Reports of visiongain provides an
informative insight into the leading companies and technologies in the sector, with an easily understood introduction to cancer at a genetic and cellular level.
Please Note: Reports are sold based on the user licenses indicated. The Publisher delivers the report in Flash format via the publisher website, allowing viewing and printing capabilities only. Within one to two business days after placing the order, the Publisher will email the client with information on accessing their purchase. Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Get Full Details About This Report >>
|
